News

This is the second agreement with QIAGEN within nine months; the first licence agreement was signed for the amplification buffer technology developed by the team led by renowned

With the agreement, Hitachi High-Technologies will gain exclusive rights to market Nanosphere products in Japan. The two companies also plan to collaborate on assay and platform development. Hitachi

Nexavar (sorafenib) tablet is an anticancer medicine for the treatment of patients with unresectable HCC. Stivarga is an inhibitor of multiple kinases involved in normal cellular functions and

The new software widens the functionality of Definiens’ current product portfolio and offers a high quality control advantage, with up to a two-fold reduction in hands on time

Xofigo is the first alpha particle-emitting radioactive therapeutic agent that has showed improvement in overall survival (OS) and delay in time to first symptomatic skeletal event (SSE) compared

The enrolment of the first patient in Phase 1b/2 INvestigation of anti-Notch Antibody therapy with Cisplatin and etoposide in small cell Lung carcinoma Efficacy and safety (PINNACLE) trial

The central alpha2A-adrenergic receptor agonist is indicated as monotherapy and adjunctive therapy to stimulant medications for Attention De?cit Hyperactivity Disorder (ADHD). TWi Pharmaceuticals president Dr. Calvin Chen said,

According to the license and supply deal, Ligand has earned a $500,000 milestone payment. Ligand executive vice president and chief operating officer Matthew Foehr said, "Rib-X is an

The investigational therapy that is currently in Phase 2 development comprises two recombinant, gluten specific enzymes (a cysteine protease (EP-B2) and a prolyl endopeptidase (PEP)), that degrade gluten